Cumulative Incidence of Cancer Screening for Breast, Cervical, Prostate, and Colorectal Cancer in Patients With Rheumatoid Arthritis

REFERENCES

1. 1.↵
   1. van Nies JA,
   2. Tsonaka R,
   3. Gaujoux-Viala C,
   4. Fautrel B,
   5. van der Helm-van Mil AH.

   Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 2015;74:806-12.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Sokka T,
   2. Abelson B,
   3. Pincus T.

   Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26 (Suppl 51):S35-61.

   OpenUrlPubMed
3. 3.↵
   1. England BR,
   2. Sayles H,
   3. Michaud K, et al

   . Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res 2016;68:36-45.

   OpenUrlCrossRef
4. 4.↵
   1. Simon TA,
   2. Thompson A,
   3. Gandhi KK,
   4. Hochberg MC,
   5. Suissa S.

   Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015;17:212.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Smitten AL,
   2. Simon TA,
   3. Hochberg MC,
   4. Suissa S.

   A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Wilton KM,
   2. Matteson EL.

   Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther 2017;4:333-47.

   OpenUrlPubMed
7. 7.↵
   1. Davis JM III

   . Overview of the associations between cancer and rheumatic disease. Rheum Dis Clin North Am 2020;46:417-27.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. De Cock D,
   2. Hyrich K.

   Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best Pract Res Clin Rheumatol 2018;32:869-86.

   OpenUrlCrossRef
9. 9.↵
   1. Sebbag E,
   2. Molina-Collada J,
   3. Ndoye R, et al

   . Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis 2025;84:643-52.

   OpenUrlPubMed
10. 10.↵
    1. Sebbag E,
    2. Lauper K,
    3. Molina-Collada J, et al

    . 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis 2024 Dec 20 (Epub ahead of print).
11. 11.↵
    1. Kim SC,
    2. Schneeweiss S,
    3. Myers JA,
    4. Liu J,
    5. Solomon DH.

    No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis Rheum 2012;64:3076-82.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Widdifield J,
    2. Ivers NM,
    3. Bernatsky S, et al

    . Primary care screening and comorbidity management in rheumatoid arthritis in Ontario, Canada. Arthritis Care Res 2017;69:1495-503.

    OpenUrlCrossRef
13. 13.↵
    1. Kremers HM,
    2. Bidaut-Russell M,
    3. Scott CG,
    4. Reinalda MS,
    5. Zinsmeister AR,
    6. Gabriel SE.

    Preventive medical services among patients with rheumatoid arthritis. J Rheumatol 2003;30:1940-7.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Kahn KL,
    2. MacLean CH,
    3. Liu H, et al

    . The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease care. Med Care 2007;45:55-65.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. St Sauver JL,
    2. Grossardt BR,
    3. Yawn BP,
    4. Melton LJ III,
    5. Rocca WA.

    Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol 2011;173:1059-68.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Aletaha D,
    2. Neogi T,
    3. Silman AJ, et al

    . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. US Preventive Services Task Force

    . Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151:716-26, W-236.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Siu AL; US Preventive Services Task Force

    . Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:279-96.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. US Preventive Services Task Force;
    2. Curry SJ,
    3. Krist AH,
    4. Owens DK, et al

    . Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;320:674-86.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. US Preventive Services Task Force;
    2. Grossman DC,
    3. Curry SJ,
    4. Owens DK, et al

    . Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319:1901-13.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. US Preventive Services Task Force;
    2. Bibbins-Domingo K,
    3. Grossman DC,
    4. Curry SJ, et al

    . Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016;315:2564-75.

    OpenUrlCrossRefPubMed
22. 22.
    1. US Preventive Services Task Force;
    2. Davidson KW,
    3. Barry MJ,
    4. Mangione CM, et al

    . Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2021;325:1965-77.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Gupta S.

    Screening for colorectal cancer. Hematol Oncol Clin North Am 2022;36:393-414.

    OpenUrlPubMed
24. 24.↵
    1. Deyo RA,
    2. Cherkin DC,
    3. Ciol MA.

    Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Olusola P,
    2. Banerjee HN,
    3. Philley JV,
    4. Dasgupta S.

    Human papilloma virus-associated cervical cancer and health disparities. Cells 2019;8:622.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Melnikow J,
    2. Henderson JT,
    3. Burda BU,
    4. Senger CA,
    5. Durbin S,
    6. Weyrich MS.

    Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;320:687-705.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. National Cancer Institute

    . Surveillance, Epidemiology, and End Results Program. Cancer stat facts: cervical cancer. [Internet. Accessed July 31, 2025.] Available from: https://seer.cancer.gov/statfacts/html/cervix.html#:~:text=Rate%20of%20New%20Cases%20and%20Deaths%20per%20100%2C000%3A,and%20based%20on%202018%E2%80%932022%20cases%20and%202019%E2%80%932023%20deaths
28. 28.↵
    1. Moscicki AB,
    2. Flowers L,
    3. Huchko MJ, et al

    . Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis 2019;23:87-101.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Hanly JG,
    2. Thompson K,
    3. Skedgel C.

    A longitudinal study of ambulatory physician encounters, emergency room visits, and hospitalizations by patients with rheumatoid arthritis: a 13-year population health study. J Rheumatol 2017;44:1421-8.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Apovian CM.

    Obesity: definition, comorbidities, causes, and burden. Am J Manag Care 2016;22 (Suppl):S176-85.

    OpenUrlPubMed
31. 31.↵
    1. Ou J,
    2. Zou L,
    3. Wu Y, et al

    . Causal inference between rheumatoid arthritis and prostate cancer. Clin Exp Med 2023;23:4681-94.

    OpenUrlPubMed
32. 32.↵
    1. Wheeler AM,
    2. Roul P,
    3. Yang Y, et al

    . Risk of prostate cancer in US veterans with rheumatoid arthritis. Arthritis Care Res 2023; 75:785-92.

    OpenUrl
33. 33.↵
    1. Bergengren O,
    2. Pekala KR,
    3. Matsoukas K, et al

    . 2022 Update on prostate cancer epidemiology and risk factors – a systematic review. Eur Urol 2023;84:191-206.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Barsouk A,
    2. Saginala K,
    3. Aluru JS,
    4. Rawla P,
    5. Barsouk A.

    US cancer screening recommendations: developments and the impact of COVID-19. Med Sci 2022;10:16.

    OpenUrl
35. 35.↵
    1. D’Silva KM,
    2. Wallace ZS.

    COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol 2021;33:255-61.

    OpenUrlCrossRefPubMed